Login to Your Account



Amgen's Denosumab Meets All Endpoints in Long Awaited Trial

By Jennifer Boggs


Tuesday, July 29, 2008
The news, released after the market close Friday, gave a big boost to Amgen investors, who have been looking anxiously at the RANK ligand inhibitor to help the company gain back ground lost by its safety-plagued ESA franchise. Top-line data from the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every Six Months) trial showed that denosumab, given as a subcutaneous injection, resulted in a statistically significant reduction in the incidence of new vertebral fractures compared to placebo, the primary endpoint. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription